Literature DB >> 15311059

Expression profiles of androgen independent bone metastatic prostate cancer cells indicate up-regulation of the putative serine-threonine kinase GS3955.

Marco Bisoffi1, Irena Klima, Ekaterina Gresko, Paul N Durfee, William C Hines, Jeffrey K Griffith, Urs E Studer, George N Thalmann.   

Abstract

PURPOSE: We established gene expression profiles by gene array analysis in the LNCaP model of human prostate cancer progression and evaluated genes differentially expressed in the androgen independent and bone metastatic C4-2 cell line compared to the androgen dependent and nonmetastatic parental LNCaP cell line.
MATERIALS AND METHODS: Gene expression profiles were generated using Atlas cDNA arrays (Clontech, Palo Alto, California), comprising 1,176 genes. Intrinsic expression of the novel serine/threonine kinase GS3955 in LNCaP, C4-2 and PC-3 prostate cancer cells, and expression when stimulated with growth factors, was monitored by real-time reverse transcriptase-polymerase chain reaction. Furthermore, expression in human tumor specimens was evaluated. Cellular localization of GS3955 protein was analyzed by expressing it as a fusion with green fluorescent protein.
RESULTS: Comparable numbers of genes were up-regulated and down-regulated in C4-2 compared to LNCaP. The novel serine/threonine kinase GS3955 was markedly up-regulated (greater than 40-fold) in C4-2, differentially regulated in LNCaP and C4-2 by insulin-like growth factor-1, and variably expressed in human prostate tumor specimens. Moreover, GS3955 was shown to localize in the cell cytoplasm and nucleus.
CONCLUSIONS: Differential expression and mitogenic regulation of the serine/threonine kinase GS3955 in LNCaP and C4-2 suggest its functional involvement in the development of androgen independence and/or metastatic potential. GS3955 is also expressed in human prostate cancer specimens and further analysis may provide insights into the biology of prostate cancer progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15311059     DOI: 10.1097/01.ju.0000135117.40086.fa

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia.

Authors:  Karen Keeshan; Yiping He; Bas J Wouters; Olga Shestova; Lanwei Xu; Hong Sai; Carlos G Rodriguez; Ivan Maillard; John W Tobias; Peter Valk; Martin Carroll; Jon C Aster; Ruud Delwel; Warren S Pear
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

2.  Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression.

Authors:  Asa J Oudes; Jared C Roach; Laura S Walashek; Lillian J Eichner; Lawrence D True; Robert L Vessella; Alvin Y Liu
Journal:  BMC Cancer       Date:  2005-07-22       Impact factor: 4.430

3.  Tribbles-2 is a novel regulator of inflammatory activation of monocytes.

Authors:  Katalin Eder; Hongtao Guan; Hye Y Sung; Jon Ward; Adrienn Angyal; Michelle Janas; Gabriella Sarmay; Erno Duda; Martin Turner; Steven K Dower; Sheila E Francis; David C Crossman; Endre Kiss-Toth
Journal:  Int Immunol       Date:  2008-10-24       Impact factor: 4.823

4.  Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines.

Authors:  Lien Spans; Christine Helsen; Liesbeth Clinckemalie; Thomas Van den Broeck; Stefan Prekovic; Steven Joniau; Evelyne Lerut; Frank Claessens
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.